Aytu BioPharma Inc

AYTU | Healthcare | NASDAQ
$1.90
-0.07 (-3.55%)

Key Metrics

Market Cap
$11.93M
P/E Ratio
-0.84
EPS
$-2.26
Beta
N/A
Dividend Yield
N/A
ROE
-47.40%
Current Ratio
1.26

Company Information

Industry
Drug Manufacturers Specialty Generic

About Aytu BioPharma Inc

Aytu Biopharma Inc a specialty pharmaceutical company focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally The company offers Adzenys XRODT for the treatment of attention deficit hyperactivity disorder ADHD in patients from 6 years and older Cotempla XRODT for the treatment of ADHD in patients from 6 to 17 years old and Adzenys ER an oral suspension for the treatment of ADHD in patients from 6 years and older It also provides Karbinal ER a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies PolyViFlor and TriViFlor prescription supplements for infants and children for the treatment of fluoride deficiency Tuzistra XR a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension and ZolpiMist an oral spray for the treatment of insomnia The company was formerly known as Aytu BioScience Inc and changed its name to Aytu Biopharma Inc in March 2021 Aytu Biopharma Inc was incorporated in 2015 and is headquartered in Englewood Colorado

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-05-14 $0.20 $-0.17 +-217.6%
2025-02-12 $-0.28 $-0.28 +0.0%
2024-11-13 $-0.20 $-0.34 +-41.2%
2024-09-26 $-0.82 $-0.45 82.2%

Financial Ratios (TTM)

Gross Margin
69.04%
Operating Margin
-11.79%
Net Margin
-20.43%
ROA
-10.90%
Price to Book
0.68
Price to Sales
0.18